2026-01-15 - Analysis Report
**Johnson & Johnson Stock Report**
==============================

**Company Overview**
------------------

Johnson & Johnson is a multinational healthcare company.

**Return Rate Comparison**
-------------------------

* Ticker: JNJ
* Comparison stock: S&P 500 (VOO)
* Cumulative return of review stock: **56.96%**
* Cumulative return of comparison stock: **93.94%**
* Divergence: **-37.00** (max: 13.60, min: -62.50, relative divergence: **33.50%**)

**Alpha, Beta Analysis**
------------------------

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 6.0% | 16.8% | 3.0% | 0.7 | 317.9B |
| 2017-2019  | 18.0% | 16.8% | 1.0% | 0.7 | 359.3B |
| 2018-2020  | 19.0% | 16.8% | -2.0% | 0.7 | 387.7B |
| 2019-2021  | 32.0% | 10.7% | -12.0% | 0.6 | 421.4B |
| 2020-2022  | 8.0% | 13.8% | 10.0% | 0.5 | 435.2B |
| 2021-2023  | -18.0% | 13.8% | -19.0% | 0.3 | 386.1B |
| 2022-2024  | -30.0% | 13.8% | -50.0% | 0.2 | 356.3B |
| 2023-2025  | 30.0% | 13.8% | -32.0% | 0.1 | 509.8B |

**Recent Stock Price Fluctuations**
-------------------------------

* Close: **$213.65**
* Last-market: **$218.45** (price: 218.45, previousClose: 213.65, change: 2.25)
* 5-day SMA: **$208.20**
* 20-day SMA: **$207.79**
* 60-day SMA: **$200.65**

**RSI, PPO Index Indicators, and Delta_Previous_Relative_Divergence**
-------------------------------------------------------------------

* Market Risk Indicator (MRI): **0.70** (0.9~1.0: High Investment Recommended, 0.7~0.9: Medium Investment, 0.4~0.7: Low Investment, <0.4: Very Risky)
* RSI: **63.51**
* PPO: **0.02**
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: Medium (MRI 0.70)
* Recent (20 days) relative divergence change: **7.70** (+): improving
* 7-day Rank change: **-31** (-): rank down
* 7-day Dynamic Expected Return change: **3.80** (+): improving
* Expected Return (%): **-48.40%**
* If {'price': 218.45, 'previousClose': 213.65, 'change': 2.25} is large, reflect the fluctuation issue (sharp rebound, sharp decline).

**Recent News & Significant Events**
-----------------------------------

* [2026-01-14] Fund Update: 434,743 JOHNSON & JOHNSON (JNJ) shares added to Canoe Financial LP portfolio - Quiver Quantitative (news.google.com)
* [2026-01-14] Is Johnson & Johnson (JNJ) Still Fairly Priced After Its Strong 12-Month Rally? - simplywall.st (news.google.com)
* [2026-01-14] Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know - Yahoo Finance (news.google.com)
* [2025-12-30] More Upside For JNJ Stock In 2026? - Forbes (news.google.com)
* [2026-01-13] Johnson & Johnson's $1 billion loss from robotics takeover reduced by Delaware top court - Reuters (news.google.com)
* [2026-01-14] ORG Partners LLC Has $1.97 Million Holdings in Johnson & Johnson $JNJ - MarketBeat (news.google.com)

**Analyst Opinions**
-------------------

**Analyst Consensus:**

* Key: Buy
* Mean (1=StrongBuy~5=Sell): 2.16 (~Buy)
* Opinions: 24
* Target Price (avg/high/low): 212.00 / 240.00 / 155.00

**Recent Earnings Analysis**
---------------------------

| Date | EPS | Revenue |
|-----|----|---------|
| 2025-10-22 | 2.14 | $23.99B |
| 2025-07-24 | 2.3 | $23.74B |
| 2025-04-23 | 4.57 | $21.89B |
| 2024-10-23 | 1.12 | $22.47B |
| 2025-10-22 | 1.12 | $22.47B |

**Revenue and Profitability**
---------------------------

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $23.99B | 69.56% |
| 2025-06-30 | $23.74B | 67.87% |
| 2025-03-31 | $21.89B | 66.40% |
| 2024-12-31 | $22.52B | 68.35% |
| 2024-09-30 | $22.47B | 69.01% |

**Capital and Profitability**
---------------------------

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $79.28B | 6.50% |
| 2025-06-30 | $78.47B | 7.06% |
| 2025-03-31 | $78.11B | 14.08% |
| 2024-12-31 | $71.49B | 4.80% |
| 2024-09-30 | $70.16B | 3.84% |

**Comprehensive Analysis (Summary of Previous Items)**
----------------------------------------------------

Johnson & Johnson's stock has a cumulative return of 56.96% compared to 93.94% for the S&P 500. The stock has a medium risk level with a market risk indicator of 0.70. The recent news and significant events suggest a buy recommendation. The earnings analysis shows a decline in revenue and earnings per share. The financial information indicates a decline in profit margin and return on equity. Based on this analysis, the stock is not a good investment opportunity at this time.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.